Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Carcinoid syndrome causes
Introduction
Overview
Overview
Common causes of carcinoid syndrome include genetic disorders (multiple endocrine neoplasia type 1 and neurofibromatosis type 1) and genetic mutations (gains involving chromosomes 5, 14, 17, and 19 and losses involving chromosomes 11 and 18).
Causes
Causes
- Approximately 30-40% of patients with well-differentiated neuroendocrine tumors present with carcinoid syndrome.
- Carcinoid syndrome is predominantly associated with neuroendocrine tumors (NETs) that arise from the midgut in the setting of extensive liver metastases
- Carcinoid syndrome may be present in patients with bronchial carcinoids.[1]
- other common causes of carcinoid syndrome includes are mostly genetic:[2]
- Genetic disorders[3]
| Genetic Disorder | Tumor Location |
|---|---|
| |
|
| Type of Mutation | Chromosomes |
|---|---|
|
Gains |
|
|
Losses |
|
References
References
- ↑ Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP (August 2018). “Carcinoid syndrome: update on the pathophysiology and treatment”. Clinics (Sao Paulo). 73 (suppl 1): e490s. doi:10.6061/clinics/2018/e490s. PMC 6096975. PMID 30133565.
- ↑ Molecular genetics. National Cancer Institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq
- ↑ “Duodenal Carcinoid Tumours, Phaeochromocytoma and Neurofibromatosis: Islet Cell Tumour, Phaeochromocytoma and the Von Hippel-Lindau Complex: Two Distinctive Neuroendocrine Syndromes”. QJM: An International Journal of Medicine. 1987. doi:10.1093/oxfordjournals.qjmed.a068147. ISSN 1460-2393.
- ↑ Jakobovitz, O; Nass, D; DeMarco, L; Barbosa, A J; Simoni, F B; Rechavi, G; Friedman, E (1996). “Carcinoid tumors frequently display genetic abnormalities involving chromosome 11”. The Journal of Clinical Endocrinology & Metabolism. 81 (9): 3164–3167. doi:10.1210/jcem.81.9.8784062. ISSN 0021-972X.
- ↑ O’Shea T, Druce M (December 2017). “When should genetic testing be performed in patients with neuroendocrine tumours?”. Rev Endocr Metab Disord. 18 (4): 499–515. doi:10.1007/s11154-017-9430-3. PMC 5849652. PMID 28965289.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]